Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	16.9	25.03	25.84	92.94	106.08	200.4
Short-Term Investments	5.42	17.47	25.88	149.88	264.98	300.26
Cash & Short-Term Investments	22.32	42.5	51.73	242.82	371.07	500.66
Cash Growth	-36.75%	-17.84%	-78.70%	-34.56%	-25.88%	93.22%
Accounts Receivable	-	1.48	34.11	40.22	0.99	-
Other Receivables	-	-	-	0.8	0.8	1.95
Receivables	-	1.48	34.11	41.02	1.79	1.95
Inventory	-	10.66	9.71	1.59	-	-
Prepaid Expenses	-	-	-	-	-	20.47
Restricted Cash	-	0.15	0.15	0.15	0.19	0.19
Other Current Assets	2.45	10.12	6.18	9.51	11.57	-
Total Current Assets	24.77	64.89	101.87	295.08	384.62	523.27
Property, Plant & Equipment	11.2	41.1	58.79	74.32	79.94	62.82
Other Long-Term Assets	0.93	3.1	4.84	7.02	3.57	2.03
Total Assets	36.9	109.1	165.5	376.42	468.13	588.12
Accounts Payable	1.76	4.37	3.68	6.87	17.37	7.12
Accrued Expenses	8.95	21.2	48.53	50.41	44.91	40.34
Current Portion of Leases	2.24	13.92	12.18	13.64	2.75	1.99
Current Unearned Revenue	1.61	95.09	77.83	8	40.76	33.46
Total Current Liabilities	14.56	134.57	142.23	78.92	105.79	82.9
Long-Term Leases	15.43	31.52	45.69	58.06	25.52	13.04
Long-Term Unearned Revenue	40.22	38.62	72.19	107.24	55.71	27.8
Other Long-Term Liabilities	1.73	1.67	4.63	5.56	1.5	2.04
Total Liabilities	71.94	206.38	264.74	249.78	188.51	125.78
Common Stock	0	0	-	0.01	0.01	0.01
Additional Paid-In Capital	1,979	1,957	1,870	1,822	1,745	1,587
Retained Earnings	-2,014	-2,055	-1,969	-1,693	-1,465	-1,125
Comprehensive Income & Other	-	0.01	-0.2	-2.07	-0.37	0.3
Shareholders' Equity	-35.04	-97.28	-99.23	126.64	279.61	462.34
Total Liabilities & Equity	36.9	109.1	165.5	376.42	468.13	588.12
Total Debt	17.67	45.43	57.87	71.7	28.27	15.03
Net Cash (Debt)	4.66	-2.94	-6.15	171.12	342.8	485.63
Net Cash Growth	-	-	-	-50.08%	-29.41%	99.53%
Net Cash Per Share	0.45	-0.39	-1.45	41.94	91.49	164.13
Filing Date Shares Outstanding	7.02	5.86	4.77	3.84	3.72	3.34
Total Common Shares Outstanding	6.98	5.86	4.26	3.84	3.67	3.33
Working Capital	10.21	-69.68	-40.36	216.16	278.84	440.37
Book Value Per Share	-5.02	-16.60	-23.31	33.00	76.25	138.64
Tangible Book Value	-35.04	-97.28	-99.23	126.64	279.61	462.34
Tangible Book Value Per Share	-5.02	-16.60	-23.31	33.00	76.25	138.64
Machinery	0.48	17.67	18.66	17.82	26.05	19.18
Construction In Progress	-	-	0.16	0.03	6.33	0.88
Leasehold Improvements	0.07	0.93	0.9	0.88	50.14	50.13

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q